Mycobacterium tuberculosis: The Treatment of Active Disease

Seminars in Respiratory Infections

Volumn 18, Issue 4, 2003, Pages 292-306

  Neralla, Sridhar ^a   Glassroth, Jeffrey ^b  

^a University of Wisconsin Health   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; THIOACETAZONE;

AGRANULOCYTOSIS; ANAPHYLAXIS; ANTIBIOTIC SENSITIVITY; APLASIA; ARTHRALGIA; BONE MARROW SUPPRESSION; CHOLESTATIC HEPATITIS; CYTOPENIA; DERMATITIS; DRUG HYPERSENSITIVITY; ERADICATION THERAPY; FEVER; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEMOLYSIS; HEPATITIS; HUMAN; HYPERBILIRUBINEMIA; HYPERURICEMIA; IMPOTENCE; INTERSTITIAL NEPHRITIS; JAUNDICE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; LUNG TUBERCULOSIS; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OPTIC NERVE DISEASE; OTOTOXICITY; PARESTHESIA; PERIPHERAL NEUROPATHY; PHOTOSENSITIVITY DISORDER; PHOTOTOXICITY; PRIORITY JOURNAL; PSYCHOSIS; RASH; RELAPSE; RETROBULBAR OPTIC NEUROPATHY; REVIEW; SEIZURE; STEVENS JOHNSON SYNDROME; TENDON RUPTURE; THROMBOCYTOPENIA; TORSADE DES POINTES; TREATMENT FAILURE; UNITED STATES; UVEITIS; VOMITING;

EID: 0348141716     PISSN: 08820546     EISSN: None     Source Type: Journal    
DOI: 10.1053/S0882-0546(03)00070-7     Document Type: Review

References (57)

1. Small PM, Fujiwara PI: Management of tuberculosis in the United States. N Engl J Med 345:189-200, 2001
2. Cegielski JP, Chin DP, Espinal MA, et al: The global tuberculosis situation. Infect Dis Clin North Am 16:1-58, 2002
3. Mahmoudi A, Iseman MD: Pitfalls in the care of patients with tuberculosis. JAMA 270:65-68, 1993
4. Ellner JJ: The immune response in human tuberculosis-implications for TB control. J Infect Dis 176:1351-1359, 1997
5. Grosset J: Bacteriologic basis of short-course chemotherapy for tuberculosis. Clin Chest Med 1:231-241, 1980
6. Glassroth J: Tuberculosis, in Respiratory Infections (ed 2). Philadelphia, PA, Lippincott, 2001
7. Grange JM: The mystery of the mycobacterial persistor. Tuber Lung Dis 73:249-251, 1992
8. Medical Research Council: Long term chemotherapy in treatment of chronic pulmonary tuberculosis with cavitations. Tubercle 43:201, 1965
9. Mitchison DA, Dickinson JM: Laboratory aspects of intermittent drug therapy. Postgrad Med J 47:737-741, 1971
10. Mitchison DA: Basic mechanisms of chemotherapy. Chest 76:6, 1974 (suppl)
11. British Thoracic and Tuberculosis Association: Short course chemotherapy in pulmonary TB. Lancet 2:1102-1104, 1976
12. Dutt AK, Jones L, Stead WW: Short-course chemotherapy for tuberculosis with largely weekly INH and RIF. Chest 75:441-447, 1979
13. Guidelines for short course Tuberculosis chemotherapy. MMWR Morb Mortal Wkly Rep 1:29:9, 1980
14. A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report-results after end of chemotherapy. Am Rev Respir Dis 126:460-462, 1982
15. Hong Kong Chest Service/BMRC: Controlled trial of 4 three times weekly regimens and a daily regimen all given for six months for pulmonary TB: Second report-the results up to 24 months. Tubercle 63:89-98, 1982
16. Hong Kong Chest Service/BMRC: Controlled trial of 2,4,6 months of PZA in 6 months three times weekly regimens for smear-positive pulmonary TB, including assessment of a combined preparation of INH, RIF and PZA. Am Rev Respir Dis 143:700-706, 1991
17. Combs DL, Obrien RJ, Geiter J: USPHS tuberculosis short course trial 21: Effectiveness, toxicity and acceptability. Ann Intern Med 112:397-406, 1990
18. Cohn DL, Catlin BJ, Peterson KL, et al: A 62 dose, 6-month therapy for pulmonary and extrapulmonary TB. Ann Intern Med 112:407-415, 1990
19. Snider DE, Graczyk J, Bek E, et al: Supervised six-months treatment of newly diagnosed pulmonary TB using INH, RIF and PZA with and without STR. Am Rev Respir Dis 130:1091-1094, 1984
20. East African/BMRC: Controlled clinical trial of five short course (4-month) chemotherapy regimens in pulmonary TB. Am Rev Respir Dis 123:165-170, 1981
21. Hong Kong Chest Service/BMRC/TB Research Centre Madras: A controlled trial of 3-month, 4-month and 6-month regimens of chemotherapy for sputum smear negative pulmonary TB. Am Rev Respir Dis 139:871-876, 1989
22. ATS/CDC: Position statement: Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med 149:1359-1374, 1994
23. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Statement on treatment of tuberculosis. Am J Respir Crit Care Med 167:603-662, 2003
24. Vernon A: TB trials consortium. Am J Respir Crit Care Med 22:A252, 2000
25. Vernon A, Burman N, Benator D, et al: TB trials consortium: Acquired rifamycin monoresistance in patients with HIV related TB treated with once weekly rifapentine and INH. Lancet 353:1843-1847, 1999
26. Huebner RE, Schein MF, Bass JB Jr, et al: The tuberculin skin test. Clin Infect Dis 17:968-975, 1993
27. ATS/CDC: Targeted tuberculin testing and treatment of latent TB infection. Am J Respir Crit Care Med 161:S221-S247, 2000
28. Van Scoy RE, Wilkowske CJ: Antimycobacterial therapy. Mayo Clin Proc 74:1038-1048, 1999
29. Nolan CM, Goldberg SV, Boskin SV: Hepatotoxicity associated with INH preventative therapy. JAMA 281:1014-1018, 1999
30. Kopanoff DE, Snider DE, Caras GJ: INH related hepatitis: A USPHS cooperative surveillance study. Am Rev Respir Dis 117:991-1001, 1978
31. Bailey WC, Weill H, DeRouen TA, et al: The effect of INH on transaminase levels. Ann Intern Med 81:200-202, 1974
32. Steele MA, Burk RF, DesPrez RM: Toxic hepatitis with INH and RIF. Chest 99:465-471 1991
33. Mehta JB, Shantaveerapa H, Byrd BP, et al: Utility of rifampin blood levels in the treatment and follow up of active pulmonary TB in patients who were slow to respond to continued DOT. Chest 120:1520-1524, 2001
34. Dossing M, Wilcke JT, Peterson KT, et al: Liver injury during antituberculosis treatment: An 11 year study. Tuber Lung Dis 77:335-340, 1996
35. Doster B, Murray FJ, Newman R, et al: EMB in the initial treatment of pulmonary TBUSPHS TB therapy trials. Am Rev Respir Dis 107:177-190, 1973
36. Gollub EL, Trino R, Salmon M, et al: Co-occurance of AIDS and TB: Results of a database "match" investigation. J AIDS Hum Retrovirol 16:44-49, 1997
37. East African/BMRC: Controlled trial of 4 short course (6-month) regimens for treatment of pulmonary TB. Third Report. Lancet 2:237-240, 1974
38. Joint Committee on Study of STR: The effects of STR on TB in man. JAMA 135:634-641. 1947
39. Weis SE, Slocum PC, Blais FX, et al: The effect of directly observed therapy on rates of drug resistance and relapse in TB. N Engl J Med 330:1179-1184, 1994
40. Chaulk CP, Kazandjian VA: Consensus statement: DOT for the treatment completion of pulmonary TB. JAMA 279:943-947, 1998
41. Burman WJ, Dalton CB, Cohn DL, et al: A cost effective analysis of DOT vs: self administered therapy for treatment of TB. Chest 112:63-70, 1997
42. Hong Kong Chest Service/BMRC: Five year follow up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 136:1339, 1987
43. BMRC: Controlled trial of 6-months and 9-months regimens of daily and intermittent streptomycin plus INH plus PZA for pulmonary TB. Am Rev Respir Dis 115:727, 1977
44. Espinal MA, Laszlo A, Simonsen L, et al: Global trends in resistance to antituberculosis drugs. N Engl J Med 344:1294-1303, 2001
45. Moore M, Onorato IM, McCray E, et al: Trends in drug resistant TB in the U.S, 1993-1996. JAMA 278:833-837, 1997
46. Tahaoglu K, Torun T, Sevium T, et al: The treatment of multi-drug resistant TB in Turkey. N Engl J Med 345:170, 2001
47. Iseman MD: Treatment of MDR-TB. N Engl J Med 329:784, 1993
48. Condos R, Rom WN, Schluger NW: Treatment of MDR pulmonary TB with interferon gamma via aerosol. Lancet 349:1513, 1997
49. Briggs GG: Drugs in pregnancy and lactation (5th ed). Maryland, Williams and Wilkins, 1998
50. Tramontana JM, Utaipat U, Molloy A, et al: Thalidomide treatment reduces tumor necrosis factor production and enhances weight gain in patients with pulmonary TB. Mol Med 1:384-397, 1995
51. Johnson B: Recombinant IL-2 adjunctive therapy in MDR-TB. Novartis Foundation Symposium 217:99-106, 1998
52. Karyadi E, West CE, Schultink W, et al: A double blinded placebo controlled study of vitamin A and zinc supplementation in persons with TB in Indonesia. Am J Clin Nutr 75:720-727, 2002
53. Holland SM, Eisenstein EM, Kuhns DB, et al: Treatment of disseminated NTM infection with INF-gamma. N Engl J Med 330:1348-1355, 1994
54. Schraufnagel DE: Tuberculosis treatment for the beginning of the next century. Int J Tuber Lung Dis 3:651-662, 1999
55. Hong Kong Chest Service/BMRC: A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of pulmonary TB resistant to INH, STR and RIF. Tuber Lung Dis 73:59-67, 1992
56. McKinney JD, Bentrap K, Munoz-Elias EJ, et al: Persistence of MTB in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406:683-685, 2000
57. Mazurek GH, Villarino ME: Guidelines for using the QantiFERON-TB test for diagnosing latent mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 152:15-18, 2003